Board of Directors

Henrijette Richter is Managing Partner at Sofinnova Partners. She joined the firm in 2014.

Henrijette’s investments and board involvements include Mozart Therapeutics, Muna Therapeutics, Nitrase Therapeutics, NodThera, Twentyeight-Seven Therapeutics, Asceneuron, Delinia (sold to Celgene), and iOmx Therapeutics. Prior to Sofinnova, she was part of the team that founded Novo Seeds in 2007, and as an Investment Director, was instrumental in the creation, financing, and building of companies such as Orphazyme (ORPHA.CO; ORPH), Avilex Pharma, EpiTherapeutics (sold to Gilead), and Lysogene (LYS, Euronext Paris). Henrijette holds a combined PhD and Industrial Scientist degree in molecular biology from the University of Copenhagen and Novo Nordisk A/S and did a postdoctoral fellowship at the MIT Center for Cancer Research in Massachusetts.

Luc is a Managing Partner at Droia Ventures since early 2020.

Luc​ currently serves as Droia’s representative on the Boards of Montis Biosciences (Chairman), Vaderis, Volastra, QurAlis, Vico Therapeutics (Chairman), and Alesta (Chairman). Prior to joining the VC world, he was an executive for over 20 years in several biotech companies. Luc was a cofounder of Vico Therapeutics and acted as their CEO until 2020. He is also a cofounder of Pharvaris. Luc was Chief Executive Officer of Tusk Therapeutics from May 2015 until its acquisition by Roche in September 2018. He joined Tusk from Prosensa Holding N.V., where he served as Chief Business Officer and Senior Vice President of Business Development for a period of seven years until its acquisition by BioMarin Pharmaceutical Inc. Earlier in his career, Luc served as Vice President of Business Development at TiGenix, Director of Business Development at Methexis Genomics, and a consultant at Arthur D. Little. Luc holds a PharmD degree and a postgraduate degree in business economics from the University of Leuven (Belgium) and an MBA from Vlerick Management School (Belgium). He also serves on the Board of Directors of PanTera (Chairman), Cascador Health (where he is a cofounder), and a not-for-profit organization.

Laia joined Sanofi Ventures in 2018 as a Partner. She focuses on biotech investments and company creation.

Prior to Sanofi, Laia served as Investment Director for Ysios Capital, where she led investments and served on the board of multiple early-stage biotech companies. Earlier in her career, Laia was part of the European New Business Development team of Janssen-Cilag, a pharmaceutical company part of the Johnson & Johnson group, where she assessed commercial and scientific licensing opportunities. Previously, she worked as a researcher in the UK at companies such as Spirogen (now AstraZeneca), Medivir, and UCB-Celltech. Laia’s active investments include Eligo Bioscience, Granite Bio, Muna Therapeutics, NodThera, OMass Therapeutics, QurAlis, SpliceBio, T-Therapeutics, and Therini Bio. Previous investments and board roles include Lava Therapeutics (LVTX). Laia graduated in chemistry from the University of Barcelona, where she also completed a Master of Science and a PhD with honors. Laia holds an MBA from Cambridge Judge Business School, University of Cambridge, where she focused on biotechnology, healthcare, and finance.